Ono Pharmaceutical Co Ltd - Company Profile
Powered by 
All the data and insights you need on Ono Pharmaceutical Co Ltd in one report.
$295
- Save hours of research time and resources with
our up-to-date Ono Pharmaceutical Co Ltd Strategy Report
- Understand Ono Pharmaceutical Co Ltd position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Ono Pharmaceutical Co Ltd (Ono Pharmaceutical) is an immuno-oncology company that provides research, development, manufacture and sale of prescription pharmaceuticals and diagnostic reagents. Its product portfolio includes medicines for the treatment of type II diabetes, overactive bladder, osteoporosis, cancer, chemotherapy-induced nausea and vomiting, osteoporosis, Alzheimer’s disease, peripheral circulatory disorder, bronchial asthma and allergic rhinitis, among others for the treatment of cancer. The company also offers products in various formulations such as capsules, patches, dry syrup, tablets, injections, and intravenous infusions. Ono Pharmaceutical has manufacturing facilities includes Joto Product Development Center, Yamaguchi Plant, and Fujiyama Plant. It offers products in the Americas, Europe, and Asia. Ono Pharmaceutical is headquartered in Osaka, Japan.
Headquarters
Japan
Address
1-8-2, Kyutaro-Machi, Chuo-Ku, Osaka-Shi, 541-8564
Website
www.ono-pharma.com
Telephone
81 6 62635670
No of Employees
3,761
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
4528 (TYO)
Revenue (2022)
$3.3B
23.8%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
40%
(2022 vs 2021)
Market Cap*
$7.8B
Net Profit Margin (2022)
XYZ
13.2%
(2022 vs 2021)
* As of and is in US$
Ono Pharmaceutical Co Ltd premium industry data and analytics
Products and Services
| Products | Services | Brands |
|---|---|---|
| Foipan Tablets | Supply | Glactiv |
| Glactiv Tablets | Marketing | FORXIGA |
| Kinedak Tablets | Recalbon | |
| XYZ | XYZ | |
| XYZ | XYZ | |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2024 | Contracts/Agreements | In March, the company announced a drug discovery collaboration with Sibylla Biotech to secure access to Sibylla’s cutting-edge Pharmacological Protein Inactivation by Folding Intermediates Targeting technology to create candidates for multiple therapeutic targets in the field of Central Nervous System disorders. |
| 2024 | Contracts/Agreements | In March, the company entered into an agreement with Harvard University aimed at validating innovative therapeutic targets. |
| 2024 | Contracts/Agreements | In February, the company signed an agreement with Epsilon Molecular Engineering to create novel VHH antibodies. |
Competitor Comparison
| Key Parameters | Ono Pharmaceutical Co Ltd | Chugai Pharmaceutical Co Ltd | Sumitomo Pharma Co Ltd | Kyowa Kirin Co Ltd | Shionogi & Co Ltd |
|---|---|---|---|---|---|
| Headquarters | Japan | Japan | Japan | Japan | Japan |
| City | Osaka-Shi | Chuo-Ku | Osaka-Shi | Chiyoda-Ku | Osaka-Shi |
| State/Province | Osaka | Tokyo | Osaka | Tokyo | Osaka |
| No. of Employees | 3,761 | 7,771 | 6,250 | 5,974 | 5,680 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Gyo Sagara | Chief Executive Officer; Director; President | Executive Board | 2008 | - |
| Toshihiro Tsujinaka | Director; Executive Director Corporate Strategy & Planning; Senior Executive Officer | Executive Board | 2022 | - |
| Kiyoaki Idemitsu | Director - Clinical Development; Corporate Executive Officer; Director | Executive Board | 2021 | - |
| Toichi Takino, Ph.D | Director; Executive Director- Discovery & Research; Senior Executive Officer | Executive Board | 2021 | - |
| Masayuki Tanigawa | Director - Corporate Development and Strategy | Executive Board | 2023 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward